Results 91 to 100 of about 19,643 (211)

Ewing Sarcoma

Clinical Pediatric Hematology-Oncology, 2019
Ewing sarcoma is the second most frequently occurring malignant tumor of the bone and soft tissue in adolescents and young adults. Genetically, Ewing sarcoma is characterized by balanced chromosomal translocation in which a member of FET gene family is ...
Hee Young Ju
doaj   +1 more source

Actinomycin Derivatives: Structural Diversification and Biological Activities

ChemMedChem, Volume 21, Issue 15, 14 August 2026.
Actinomycins are chromopeptide antibiotics exhibiting remarkable structural diversity and broad bioactivity. This review traces their development from naturally occurring D‐, X‐, A‐, G‐, Y‐, and Z‐type analogs to precursor‐directed, synthetic, and semisynthetic derivatives.
Özge Can, Erdal Bedir
wiley   +1 more source

Venous Thromboembolism in Pediatric Bone Sarcoma Patients: A 10‐Year, Single‐Institution Experience Encompassing the COVID‐19 Pandemic

Pediatric Blood &Cancer, Volume 73, Issue 8, August 2026.
ABSTRACT Background Osteosarcoma (OS) and Ewing sarcoma (EWS) are the most common primary bone cancers in children, but acute thrombosis is poorly characterized in this population. Our study evaluated the rates of venous thromboembolism (VTE) and associated risk factors in pediatric patients with bone sarcomas treated over a 10‐year period encompassing
Sarah Kappa, Shou Xu, Mark Zobeck, Sarah E. Sartain, Nino Rainusso, Lisa Wang, Nicole Montgomery, Paige Wheaton, Sarah Whittle   +8 more
wiley   +1 more source

Increased Risk of Sarcomas in Children With Congenital Anomalies: Findings From the Genetic Overlap Between Anomalies and Cancer in Kids (GOBACK) Registry Linkage Study

Pediatric Blood &Cancer, Volume 73, Issue 8, August 2026.
ABSTRACT Background Pediatric sarcomas are a heterogeneous group of tumors that contribute disproportionately to cancer mortality in children. Although congenital anomalies are among the strongest known risk factors for childhood cancer, the risk of specific sarcoma subtypes among affected individuals has not yet been thoroughly evaluated. Procedure We
Russ Wolters, Ji Yun Tark, Tiffany M. Chambers, Tania A. Desrosiers, Michael E. Scheurer, Charles Shumate, Wendy N. Nembhard, Mahsa M. Yazdy, Eirini Nestoridi, Amanda E. Janitz, Jean Paul Tanner, Russell S. Kirby, Jason L. Salemi, Yao Yu, Chad D. Huff, Sharon E. Plon, Philip J. Lupo, Jeremy M. Schraw   +17 more
wiley   +1 more source

Harnessing MDM2‐Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma

Advanced Science, Volume 13, Issue 45, 13 August 2026.
MDM2 dependency in pediatric sarcomas is driven by a novel p53‐independent oncogenic cistrome alongside canonical p53 pathway suppression. This study introduces MDM2‐recruiting transcriptional and epigenetic machinery degraders (MDM2‐TEMADs) as a novel precision oncology modality.
Jiawei Zhou, Xian Guan, Nan Li, Ying Zhang, Long Xie, Xingze Huang, Zhipeng Zhu, Zhuolin Ren, Xiaoyan Yu, Hanjun Guo, Yuanfang Wu, Lin Ma, Suya Zheng, Jingyao Zhang, Jiyang Liu, Victor Kuanmin Lee, Wenhao Chen, H. Phillip Koeffler, Jinhu Wang, Xin Han, Ye Chen, Liang Xu   +21 more
wiley   +1 more source

A Non‐Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non‐Small Cell Lung Cancer

Advanced Science, Volume 13, Issue 46, 17 August 2026.
A non‐canonical core transcriptional regulatory circuit, composed of ID3, SMAD3, and NR2F2, drives Osimertinib resistance in non‐small cell lung cancer through super‐enhancer‐mediated activation of EPAS1, which couples neuroendocrine differentiation with ferroptosis evasion.
Aochu Liu, Zhenguo Liu, Lizhen Jiang, Andong Huang, Xinqing Lin, Xinyue Li, Bingyuan Liu, Shiwen Hu, Qiang Pan, Junjun Huang, Liyuan Yin, Liling Jiang, Wei Yi, Wenjun Mao, Yueyuan Zheng, Xianping Shi   +15 more
wiley   +1 more source

Circulating Mitochondrial DNA Measures Across Malignancies: Diagnostic Accuracy and Prognostic Associations

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Circulating mitochondrial DNA is being investigated as a liquid‐biopsy biomarker because of its high copy number and release during cellular stress. However, diagnostic estimates vary across tumor types and assays, and prognostic studies have measured both cell‐free mtDNA and cellular blood‐derived mtDNA, which are not analytically ...
Ziying Zhang, Ying Jiang, Yu Gong, Hui Xie, Yaqian Han, Peng Chen   +5 more
wiley   +1 more source

Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma

Nature Communications
Ewing sarcoma is a pediatric bone and soft tissue tumor treated with chemotherapy, radiation, and surgery. Despite intensive multimodality therapy, ~50% patients eventually relapse and die of the disease due to chemoresistance.
Le Yu, Yu Deng, Xiaodong Wang, Charlene Santos, Ian J. Davis, H. Shelton Earp, Pengda Liu   +6 more
doaj   +1 more source

Drug Resistance in Multiple Myeloma: Tumor‐Intrinsic Mechanisms and the Bone Marrow Microenvironment

Cell Biochemistry and Function, Volume 44, Issue 8, August 2026.
ABSTRACT Multiple myeloma (MM) is a malignant plasma cell disorder, and despite substantial improvements in prognosis achieved through chemotherapy, immunotherapy, and autologous stem cell transplantation, most patients ultimately develop relapsed or refractory disease. Drug resistance (DR) is increasingly recognized as a dynamically evolving ecosystem
Yixuan Chen, Wenming Huang, Mingxuan Tang, Xiaotao Wang   +3 more
wiley   +1 more source

Suicide gene therapy targeting ewing sarcoma via an ewing-specific GGAA promoter

Scientific Reports
We recently demonstrated that GGAA promoters (GGAAprom) can be used to drive the expression of therapeutic genes (i.e., Cas9) in vitro and in vivo in a highly specific way in Ewing sarcoma cells.
Saint T. Cervera, Selene Martínez, María Iranzo-Martínez, Raquel M. Melero-Fernández de Mera, Javier Alonso   +4 more
doaj   +1 more source